PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Similar documents
Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

Approved for public release; distribution unlimited

TITLE: Maximizing Energy After Traumatic Brain Injury: A Novel Intervention

TITLE: Post-Traumatic Headache and Psychological Health: Mindfulness Training for Mild Traumatic Brain Injury

CONTRACTING ORGANIZATION: UNIVERSITY OF ILLINOIS Chicago, IL 60612

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease

Promote Adjustment during Reintegration following Deployment

Award Number: W81XWH

Detection of Prostate Cancer Progression by Serum DNA Integrity

AD (Leave blank) TITLE: Trial of Naltrexone and Dextromethorphan for Gulf War Veterans Illnesses

TITLE: TREATMENT OF ENDOCRINE-RESISTANT BREAST CANCER WITH A SMALL MOLECULE C-MYC INHIBITOR

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

Award Number: W81XWH TITLE: "Longitudinal Study of a Novel Performance-based Measure of Daily Function."

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

CONTRACTING ORGANIZATION: Cleveland Clinic Foundation Cleveland, OH 44195

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine, New York, NY 10029

TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness

TITLE: Homeostatic and Circadian Abnormalities in Sleep and Arousal in Gulf War Syndrome

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, TX 77030

TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone

Expression and Promoter Methylation of P16INK4A During Estrogen-Induced Mammary Carcinogenesis in the ACI Rat. Omaha, NE

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

TITLE: Prazosin for Treatment of Patients With PTSD and Comorbid Alcohol Dependence

TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1. Palo Alto, CA 94304

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

TITLE: Genetic and epigenetic biomarkers for recurrent prostate cancer after radiotherapy

Approved for public release; distribution unlimited

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland X Approved for public release; distribution unlimited

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

CONTRACTING ORGANIZATION: University of Minnesota St Paul, MN 55108

CONTRACTING ORGANIZATION: Spaulding Rehabilitation Hospital, Boston, MA 02129

AD (Leave blank) TITLE: Brief cognitive behavioral therapy for military populations

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

TITLE: Mission Connect Mild TBI Translational Research Consortium. U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cells

TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

RECIPIENT: Lankenau Institute for Medical Research, Wynnewood, PA 19096

CONTRACTING ORGANIZATION: The Chancellor, Masters and Scholars of the University of Cambridge, Clara East, The Old Schools, Cambridge CB2 1TN

TITLE: Determination of Optimum Vitamin D Nutrition in Young Women. Omaha, NE 68178

TITLE: Investigating the Role of TBX2 in the Inhibition of Senescence in Prostate Cancer

TITLE: Responsiveness of a Neuromuscular Recovery Scale for Spinal Cord Injury: Inpatient and Outpatient Rehabilitation

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, MD

Roles of microrna-mediated Drug Resistance in Tumor Stem Cells of Small Cell Lung Carcinoma

TITLE: A Phase II Trial of Androgen Suppression and Radiation Therapy with Samarium-1 53 in Localized, High-Risk, Prostate Cancer

TITLE: Gulf War Illness Evaluation of an innovative detoxification program

TITLE: Development of a Blood-Based Biomarker Panel for Indeterminate Lung Nodules

Transcription:

Award Number: W81XWH-12-2-0122 TITLE: Pediatric Susceptibility to Organophosphate-Induced Seizures and Effectiveness of Anticonvulsant Treatments PRINCIPAL INVESTIGATOR: Francis Edward Dudek CONTRACTING ORGANIZATION: University of Utah Salt Lake City, UT 84112 REPORT DATE: January 2017 TYPE OF REPORT: Final Addendum PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE 2. REPORT TYPE 3. DATES COVERED January 2017 Final Addendum 26 Sept 2014-25 Sept 2016 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER Pediatric Susceptibility to Nerve Agent-Induced Seizures and Effectiveness of Anticonvulsant Treatments 6. AUTHOR(S) Francis Edward Dudek Erika A. Scholl 5b. GRANT NUMBER W81XWH-12-2-0122 5c. PROGRAM ELEMENT NUMBER 5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER E-Mail: Erika.scholl@hsc.utah.edu, ed.dudek@hsc.utah.edu 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER University of Utah 201 S Presidents Circle Rm 408 Salt Lake City, UT 84112-9023 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT Organophosphate (OP) poisoning can result in status epilepticus (SE), and constitutes a medical emergency. Little data exist on OP-induced SE in immature animals, even though the immature brain is likely to respond differently to OPs, and the optimal therapies are also likely to differ from adults. Our previous results in designing a pediatric model to study the effects of the OP diisopropylfluorophosphate (DFP) showed that postnatal day 21 (P7) and P28 rats developed a robust, hours-long SE in response to the OP, which was a goal of the grant. However, P7 and P14 animals had few, if any, electrographic SE events and these events were all less than 1 hr. In order to further understand what may be occurring in P7 animals, we tested a 6-channel transmitter that could prove useful in determining whether electrographic seizures were focal in origin rather than generalized in these very young animals. We found that we could record EEG activity from P7 rat pups with very little noise, and the device was well tolerated. To examine whether P7 pups were even capable of sustaining electrographic seizures, we used kainic acid (KA), a direct glutamate agonist, to attempt to provoke SE. We found that while KA resulted in increased EEG activity, it was unclear whether this was indeed electrographic seizure activity. Further experiments are needed to examine any age-related effects of KA with our results from DFP.

15. SUBJECT TERMS Status Epilepticus, seizure, organophosphate, DFP, pediatric, neuronal injury, anticonvulsant, phenobarbital, propofol, midazolam, diazepam 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT a. REPORT U b. ABSTRACT U c. THIS PAGE U UU 10 18. NUMBER OF PAGES 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code)

Table of Contents Page Introduction..... 5 Body.. 5 Key Research Accomplishments... 9 Reportable Outcomes 9 Conclusion 9 References 10

Introduction Organophosphate (OP) poisoning often leads to status epilepticus (SE), a medical emergency. Often, the seizures associated with status epilepticus gradually become pharmacoresistant. Few if any studies have been undertaken on immature animals as models of OP-induced SE in the pediatric population, even though the immature brain is likely to respond differently to OPs than the adult. In addition, the optimal therapies for the pediatric population may well be different than for adults. Our ongoing work supported by this contract has shown that postnatal day 7 (P7) rat pups did not show clear, readily discernable electrographic or behavioral seizures. One possibility is that OP-induced seizures are not generalized in the immature animals, and thus a EEG system with only 1 or 2 channels (as used in our experiments) is inadequate for detecting seizures in the P7 and P14 pups. Furthermore, even in cases where DFP (a cholinergic OP compound) induced abnormal electrical activity in P7 rat pups, the EEG patterns did not appear to be clear seizures, as might be expected based on previous published research concerning administration of other more traditional chemoconvulsive compounds, such as kainic acid (KA). Therefore, it is unclear which of the following possibilities is true: (1) OP s (i.e., DFP) do or do not induce electrographic and/or behavioral seizures in immature animals, (2) DFP-induced seizure activity is present in the immature brain, but with atypical waveforms, and thus not recognized as seizure activity, or (3) DFP-induced seizures are more focal than with adult animals, and thus not detected when only one or two electrodes are used. To explore solutions to these problems as we attempt to develop animal models of OP-induced seizures and brain damage in the pediatric population, we performed additional experiments. Statement of Work this section is the original SOW for the 2014-2016 contract 1. To determine whether DFP induced seizures that were focal in nature and thus possibly not detected with one or two recording channels, we (i.e., Epitel, Inc.) developed a six-channel recording system that would cover a greater proportion of the immature rodent brain. Thus, we tested the efficacy of a six-channel transmitter in recording different regions on the brain surface of a P7 rat pup. 2. To insure that our failure to detect DFP-induced seizures in the P7 and P14 age range, we tested whether the glutamate-receptor agonist, kainate (KA), could evoke electrographic seizures in a P7 rat pup. Body 1. Our data from 2012-2014 (see final report for W81XWH-12-2-0122) suggested that P7 and P14 rat pups generated very few if any DFP-induced seizures. Since we previously used one- or two-channel transmitters, it was possible that seizures were not fully generalized and were occurring at other sites at a distance from the electrodes. We recently took advantage of a prototype, six-channel, wireless transmitter available from Epitel, Inc. for alpha testing. We found that the transmitter recorded EEG activity with very little noise from a P7 pup (Figure 1). Furthermore, due to the small size of this 5

device, the pup tolerated the transmitter even better than the previous two-channel transmitter, and we were able to record from P6 up to P15 (Figure 2). The recordings across this age range also appeared to show a discernable increase in baseline activity, which is a classical finding concerning the effects of increasing maturity on baseline EEG across this age range. These studies highlight the potential utility of the new sixchannel transmitter for future use in rat pups as young as P6. In the future, this transmitter system will allows us to detect heterogeneity in electrographic seizures as a function of location in the immature rat brain. Figure 1. A 6 channel recording of a P6 rat pup. 6

Figure 2. Record from a P7 rat pup over 11 days. The figure shows 1 channel from a 6 channel transmitter over the course of 11 days. 2. Because the cholinergic system in a week-old rat pup contains only about 30% of the M1 2. Because the cholinergic system in a week-old rat pup contains only about 30% of the M1 acetylcholine receptor, which is linked to seizure induction (Lee et al., 1990; Hamilton, et al., 1997), it is possible that seizure initiation in P7 rat pups is difficult to achieve using DFP, which has a cholinergic mechanism of action. To test if a chemoconvulsant with a glutamatergic mechanism might evoke electrographic seizures, we treated P7 rat pups with KA and recorded EEG activity via a two-channel transmitter. Figure 3 shows EEG activity after vehicle treatment, where spike-like events were present before and after vehicle treatment, but no injection-dependent increase in EEG activity was observed. Figure 4 shows the effect of KA treatment on EEG activity. Although KA administration appeared to cause increased EEG spike activity, there was a lack of rhythmicity in the EEG record, which is a hallmark of typical seizure activity. Therefore, while KA appeared to increase the overall activity of the brain, it was unclear whether this was true seizure activity. Additional experiments are required to compare KA-induced activity across different ages with our data on DFP. 7

Figure 3 Recording of P7 rat pup before (A) and after (B, C) administration of saline vehicle. 8

Figure 4. Recording of P7 rat pup before (A) and after (B, C) administration of 0.1 mg/kg KA. Key Research Accomplishments Validated the use of a 6-channel transmitter device for P7 rat pups for future examination of possible focal origin of EEG seizure activity Tested the ability of KA to elicit electrographic seizure activity in P7 rats Reportable Outcomes No data has been presented to this time. Conclusion The 6-channel recordings highlight the potential utility of the new transmitter for future use in rat pups as young as P6. In the future, this transmitter system will allows us to detect heterogeneity in electrographic seizures as a function of location in the immature rat brain. Our attempts to induce electrographic seizure activity in P7 rats using KA were inconclusive. While it appeared to increase the overall activity of the brain, it was unclear whether this was true seizure activity. Additional experiments are required to compare KA-induced activity across different ages with our data on DFP. 9

References J.E. Larsson and G. Wahlstrom, 1998. The influence of age and administration rate on the brain sensitivity to propofol in rats. Acta Anaesthesiol Scand, 42(8): 987-94. Smith, I., White, P.F., Nathanson, M., and Gouldson, R. 1997. Propofol. An update on its clinical use. Anesthesiology, 81 (4): 1005-43. 10